Immunotherapy Use in Advanced Urothelial Carcinoma

Immunotherapy Use in Advanced Urothelial Carcinoma

Episodes

Specialty:

All

Year:

All

EP. 1: Historic Perspective on Treatment of Bladder Cancer

March 16th 2017

EP. 2: Prognostic Subgroups in Advanced Bladder Cancer

March 16th 2017

EP. 3: PD-L1 Expression in Bladder Cancer

March 16th 2017

EP. 4: FDA Approval of Atezolizumab for Advanced Bladder Cancer

March 16th 2017

EP. 5: Bladder Cancer: Real-World Experience With Immunotherapy

March 16th 2017

EP. 6: Activity of Immunotherapy in the Frontline Setting

March 16th 2017

EP. 7: Chemotherapy Following Immunotherapy in Bladder Cancer

March 16th 2017

EP. 8: Update on Durvalumab for Metastatic Bladder Cancer

March 16th 2017

EP. 9: Immunotherapy Toxicity Management in Bladder Cancer

March 16th 2017

EP. 10: Combination Trials in Advanced Bladder Cancer

March 16th 2017

EP. 11: Bladder Cancer: Immunotherapy in the Perioperative Setting

March 16th 2017

EP. 12: BCG-Refractory Superficial Bladder Cancer

March 16th 2017

EP. 13: Bladder Cancer: Monoclonal Antibodies Under Investigation

March 16th 2017

EP. 14: The Future of Bladder Cancer Research

March 16th 2017

Trending on OncLive

CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care

Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications

FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS

Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma

NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer